{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137043754232192.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.pharmthera.2017.04.002"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0163725817301055?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0163725817301055?httpAccept=text/plain"}}],"dc:title":[{"@value":"Antimicrobial peptides: Role in human disease and potential as immunotherapies"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137043754232194","@type":"Researcher","foaf:name":[{"@value":"César de la Fuente-Núñez"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043754232195","@type":"Researcher","foaf:name":[{"@value":"Osmar N. Silva"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043754232193","@type":"Researcher","foaf:name":[{"@value":"Timothy K. Lu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043754232192","@type":"Researcher","foaf:name":[{"@value":"Octavio Luiz Franco"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01637258"}],"prism:publicationName":[{"@value":"Pharmacology & Therapeutics"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2017-10","prism:volume":"178","prism:startingPage":"132","prism:endingPage":"140"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0163725817301055?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0163725817301055?httpAccept=text/plain"}],"createdAt":"2017-04-21","modifiedAt":"2023-08-23","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360857593691744256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antimicrobial Activities of LL-37 Fragment Mutant-Poly (Lactic-Co-Glycolic) Acid Conjugate against Staphylococcus aureus, Escherichia coli, and Candida albicans"}]},{"@id":"https://cir.nii.ac.jp/crid/1520010381028243840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Wound healing activity and mechanism of action of antimicrobial and lipopolysaccharide-neutralizing peptides from enzymatic hydrolysates of rice bran proteins"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.pharmthera.2017.04.002"},{"@type":"CROSSREF","@value":"10.1016/j.jbiosc.2019.02.002_references_DOI_DSYPhyWiQBHfR2PmW9tVATWU9J6"},{"@type":"CROSSREF","@value":"10.3390/ijms22105097_references_DOI_DSYPhyWiQBHfR2PmW9tVATWU9J6"}]}